IGNITE™
Power Mix Injectable Stimulus
Key Benefits
- Fracture Callus Potential*
- Osteogenic Potential When combined with BMA
- Minimally Invasive and Osteoinductive Percutaneous injection with DBM
*In a canine model, segmental tibial defects injected with DBM & BMA composite demonstrated bone callus formation at 2-3 weeks post-injection. (Tiedman et al, 1991). Additionally, in vitro studies show DBM to contain differentiating and mitogenic factors necessary for callus and bone formation. It is unknown how the results of these canine and in vitro studies relate to clinical results for IGNITE™ in humans.
Tiedeman JJ, Connolly JF, Strates BS, and Lippiello L. “Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix.” Clin Orthop, 268: 294-302, 1991.
Find My Sales Rep
